ArkVax key facts
- Developer of a glycan-based vaccine technology intended to revolutionize animal vaccinology and combat antimicrobial resistance.
- Notable investors include Future Planet Capital, UK Innovation & Science Seed Fund, Biotechnology and Biological Sciences Research Council, Accelerate@Babraham, London School of Hygiene & Tropical Medicine — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch ArkVax: the Monday email on marks, rounds and moves
ArkVax funding rounds
No funding rounds for ArkVax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
ArkVax investors
6 investors are on record for ArkVax, including Future Planet Capital, UK Innovation & Science Seed Fund, Biotechnology and Biological Sciences Research Council and Accelerate@Babraham.
About ArkVax
Developer of a glycan-based vaccine technology intended to revolutionize animal vaccinology and combat antimicrobial resistance. The company's platform specializes in developing glycoconjugate vaccines through bacterial engineering, which involves genetically modifying bacterial cells to produce a sugar-based payload, enabling the livestock industry to reduce antibiotic use and safeguarding both animal and human health from zoonotic diseases.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 5
- Website
- arkvax.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
ArkVax doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.